A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis

Science Translational Medicine

Volumn 3, Issue 81, 2011, Pages

  Hayder, Myriam ^a,b,c   Poupot, Mary ^c,d   Baron, Michel ^a,b,c   Nigon, Delphine ^e   Turrin, Cédric Olivier ^f   Caminade, Anne Marie ^f   Majoral, Jean Pierre ^f   Eisenberg, Robert A ^g   Fournié, Jean Jacques ^a,c,d   Cantagrel, Alain ^a,b,c,e   Poupot, Rémy ^a,b,c   Davignon, Jean Luc ^a,b,c,e  

^a INSERM   (France)

^b CNRS   (France)

^c France   (France)

^d CANCER RESEARCH CENTER OF TOULOUSE   (France)

^e CHU PURPAN   (France)

^f LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTIINFLAMMATORY AGENT; AZABISPHOSPHONATE CAPPED DENDRIMER; AZAMONOPHOSPHONATE CAPPED DENDRIMER; COLLAGEN; COLONY STIMULATING FACTOR 1; DENDRIMER; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; POLYPROPYLENEIMINE DENDRIMER; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STROMELYSIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; TRANSCRIPTION FACTOR PU 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DRUG CARRIER; PHOSPHORUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; BONE EROSION; BONE MATRIX; CARTILAGE DEGENERATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR FELINE MCDONOUGH STRAIN SARCOMA VIRUS ONCOGENE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MONOCYTE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; ONCOGENE; ONCOGENE C FMS; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SPI1 ONCOGENE; SPLEEN CELL; SPLEEN FOCUS FORMING VIRUS PROVIRAL INTEGRATION ONCOGENE; SYNOVIUM; TH1 CELL; TH2 CELL; TREATMENT DURATION; ANIMAL; ARTHRITIS; BAGG ALBINO MOUSE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CELL PROLIFERATION; CELLS, CULTURED; DENDRIMERS; DIPHOSPHONATES; DRUG CARRIERS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; MICE, MUTANT STRAINS; OSTEOCLASTS; PHOSPHORUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79955703641     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002212     Document Type: Article

References (54)

1. C. C. Lee, J. A. MacKay, J. M. Fréchet, F. C. Szoka, Designing dendrimers for biological applications. Nat. Biotechnol. 23, 1517-1526 (2005). (Pubitemid 41752929)
2. A. R. Menjoge, R. M. Kannan, D. A. Tomalia, Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discov. Today 15, 171-185 (2010).
3. S. Shaunak, S. Thomas, E. Gianasi, A. Godwin, E. Jones, I. Teo, K. Mireskandari, P. Luthert, R. Duncan, S. Patterson, P. Khaw, S. Brocchini, Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat. Biotechnol. 22, 977-984 (2004). (Pubitemid 39014474)
4. V. Wagner, A. Dullaart, A. K. Bock, A. Zweck, The emerging nanomedicine landscape. Nat. Biotechnol. 24, 1211-1217 (2006). (Pubitemid 44564760)
5. O. Rolland, C. O. Turrin, A. M. Caminade, J. P. Majoral, Dendrimers and nanomedicine: Multivalency in action. New J. Chem. 33, 1809-1824 (2009).
6. M. Poupot, L. Griffe, P. Marchand, A. Maraval, O. Rolland, L. Martinet, F. E. L'Faqihi-Olive, C. O. Turrin, A. M. Caminade, J. J. Fournié, J. P. Majoral, R. Poupot, Design of phosphorylated dendritic architectures to promote human monocyte activation. FASEB J. 20, 2339-2351 (2006). (Pubitemid 44953864)
7. S. Fruchon, M. Poupot, L. Martinet, C. O. Turrin, J. P. Majoral, J. J. Fournié, A. M. Caminade, R. Poupot, Anti-inflammatory and immunosuppressive activation of human monocytes by a bioactive dendrimer. J. Leukoc. Biol. 85, 553-562 (2009).
8. L. Griffe, M. Poupot, P. Marchand, A. Maraval, C. O. Turrin, O. Rolland, P. Métivier, G. Bacquet, J. J. Fournié, A. M. Caminade, R. Poupot, J. P. Majoral, Multiplication of human natural killer cells by nanosized phosphonate-capped dendrimers. Angew. Chem. Int. Ed. Engl. 46, 2523-2526 (2007). (Pubitemid 46973603)
9. D. Portevin, M. Poupot, O. Rolland, C. O. Turrin, J. J. Fournié, J. P. Majoral, A. M. Caminade, R. Poupot, Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy. J. Transl. Med. 7, 82 (2009).
10. A. S. Chauhan, P. V. Diwan, N. K. Jain, D. A. Tomalia, Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromolecules 10, 1195-1202 (2009).
11. S. M. Rele, W. Cui, L. Wang, S. Hou, G. Barr-Zarse, D. Tatton, Y. Gnanou, J. D. Esko, E. L. Chaikof, Dendrimer-like PEO glycopolymers exhibit anti-inflammatory properties. J. Am. Chem. Soc. 127, 10132-10133 (2005). (Pubitemid 41045455)
12. J. Dernedde, A. Rausch, M. Weinhart, S. Enders, R. Tauber, K. Licha, M. Schirner, U. Zügel, A. von Bonin, R. Haag, Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation. Proc. Natl. Acad. Sci. U.S.A. 107, 19679-19684 (2010).
13. L. Klareskog, A. I. Catrina, S. Paget, Rheumatoid arthritis. Lancet 373, 659-672 (2009).
14. I. B. McInnes, G. Schett, Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429-442 (2007). (Pubitemid 46834849)
15. S. Herman, G. Krönke, G. Schett, Molecular mechanisms of inflammatory bone damage: Emerging targets for therapy. Trends Mol. Med. 14, 245-253 (2008).
16. J. A. Hamilton, Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8, 533-544 (2008). (Pubitemid 351913679)
17. H. Takayanagi, Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292-304 (2007). (Pubitemid 46480961)
18. J. L. Nam, K. L. Winthrop, R. F. van Vollenhoven, K. Pavelka, G. Valesini, E. M. Hensor, G. Worthy, R. Landewé, J. S. Smolen, P. Emery, M. H. Buch, Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 69, 976-986 (2010).
19. S. B. Cohen, R. K. Dore, N. E. Lane, P. A. Ory, C. G. Peterfy, J. T. Sharp, D. van der Heijde, L. Zhou, W. Tsuji, R. Newmark; Denosumab Rheumatoid Arthritis Study Group, Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299-1309 (2008). (Pubitemid 351705919)
20. S. B. Cohen, P. Emery, M. W. Greenwald, M. Dougados, R. A. Furie, M. C. Genovese, E. C. Keystone, J. E. Loveless, G. R. Burmester, M. W. Cravets, E. W. Hessey, T. Shaw, M. C. Totoritis; REFLEX Trial Group, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793-2806 (2006). (Pubitemid 44497758)
21. J.M. Kremer, R.Westhovens,M. Leon, E. Di Giorgio, R. Alten, S. Steinfeld, A. Russell,M. Dougados, P. Emery, I. F. Nuamah, G. R. Williams, J. C. Becker, D. T. Hagerty, L. W. Moreland, Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003). (Pubitemid 37409707)
22. A. Wiens, R. Venson, C. J. Correr, M. F. Otuki, R. Pontarolo, Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30, 339-353 (2010).
23. J. E. Gottenberg, P. Ravaud, T. Bardin, P. Cacoub, A. Cantagrel, B. Combe, M. Dougados, R. M. Flipo, B. Godeau, L. Guillevin, X. Le Loët, E. Hachulla, T. Schaeverbeke, J. Sibilia, G. Baron, X. Mariette; AutoImmunity and Rituximab registry and French Society of Rheumatology, Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the AutoImmunity and Rituximab registry. Arthritis Rheum. 62, 2625-2632 (2010).
24. K. G. Saag, G. G. Teng, N. M. Patkar, J. Anuntiyo, C. Finney, J. R. Curtis, H. E. Paulus, A. Mudano, M. Pisu, M. Elkins-Melton, R. Outman, J. J. Allison, M. Suarez Almazor, S. L. Bridges Jr., W. W. Chatham, M. Hochberg, C. MacLean, T. Mikuls, L. W. Moreland, J. O'Dell, A. M. Turkiewicz, D. E. Furst; American College of Rheumatology, American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762-784 (2008). (Pubitemid 351847559)
25. D. van der Woude, A. Young, K. Jayakumar, B. J. Mertens, R. E. Toes, D. van der Heijde, T. W. Huizinga, A. H. van der Helm-van Mil, Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: Results from two large early arthritis cohorts. Arthritis Rheum. 60, 2262-2271 (2009).
26. J. G. Stoll, U. Yasothan, Rheumatoid arthritis market. Nat. Rev. Drug Discov. 8, 693-694 (2009).
27. P. E. Lipsky, Are new agents needed to treat RA? Nat. Rev. Rheumatol. 5, 521-522 (2009).
28. R. Horai, S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, Y. Iwakura, Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191, 313-320 (2000). (Pubitemid 30060920)
29. H. J. Ditzel, The K/BxN mouse: A model of human inflammatory arthritis. Trends Mol. Med. 10, 40-45 (2004). (Pubitemid 38156198)
30. S. Nakae, S. Saijo, R. Horai, K. Sudo, S. Mori, Y. Iwakura, IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A. 100, 5986-5990 (2003). (Pubitemid 36576918)
31. M. Ziolkowska, A. Koc, G. Luszczykiewicz, K. Ksiezopolska-Pietrzak, E. Klimczak, H. Chwalinska-Sadowska, W. Maslinski, High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 164, 2832-2838 (2000). (Pubitemid 30115519)
32. R. E. Marx, Y. Sawatari, M. Fortin, V. Broumand, Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63, 1567-1575 (2005). (Pubitemid 41525412)
33. S. R. Goldring, Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology 42 (Suppl. 2), ii11-ii16 (2003).
34. D. Kyburz, M. Corr, The KRN mouse model of inflammatory arthritis. Springer Semin. Immunopathol. 25, 79-90 (2003).
35. F. Lioté, B. Boval-Boizard, D. Weill, D. Kuntz, J. L. Wautier, Blood monocyte activation in rheumatoid arthritis: Increased monocyte adhesiveness, integrin expression, and cytokine release. Clin. Exp. Immunol. 106, 13-19 (1996). (Pubitemid 26329373)
36. A. Rivollier, M. Mazzorana, J. Tebib, M. Piperno, T. Aitsiselmi, C. Rabourdin-Combe, P. Jurdic, C. Servet-Delprat, Immature dendritic cell transdifferentiation into osteoclasts: A novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104, 4029-4037 (2004). (Pubitemid 39620153)
37. E. M. Gravallese, Y. Harada, J. T. Wang, A. H. Gorn, T. S. Thornhill, S. R. Goldring, Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152, 943-951 (1998). (Pubitemid 28173356)
38. S. Supattapone, H. O. Nguyen, F. E. Cohen, S. B. Prusiner, M. R. Scott, Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. U.S.A. 96, 14529-14534 (1999). (Pubitemid 30000684)
39. J. O'Loughlin, I. Y. Millwood, H. M. McDonald, C. F. Price, J. M. Kaldor, J. R. Paull, Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): A dose ranging, phase I study. Sex. Transm. Dis. 37, 100-104 (2010).
40. R. Jevprasesphant, J. Penny, R. Jalal, D. Attwood, N. B. McKeown, A. D'Emanuele, The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 252, 263-266 (2003). (Pubitemid 36126635)
41. J. R. Arron, Y. Choi, Bone versus immune system. Nature 408, 535-536 (2000).
42. K. Sato, H. Takayanagi, Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr. Opin. Rheumatol. 18, 419-426 (2006). (Pubitemid 44297289)
43. F. P. Ross, S. L. Teitelbaum, avb3 and macrophage colony-stimulating factor: Partners in osteoclast biology. Immunol. Rev. 208, 88-105 (2005). (Pubitemid 41746387)
44. M. Asagiri, H. Takayanagi, The molecular understanding of osteoclast differentiation. Bone 40, 251-264 (2007). (Pubitemid 46054562)
45. I. K. Campbell, M. J. Rich, R. J. Bischof, J. A. Hamilton, The colony-stimulating factors and collagen-induced arthritis: Exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J. Leukoc. Biol. 68, 144-150 (2000).
46. J. G. Conway, H. Pink, M. L. Bergquist, B. Han, S. Depee, S. Tadepalli, P. Lin, R. C. Crumrine, J. Binz, R. L. Clark, J. L. Selph, S. A. Stimpson, J. T. Hutchins, S. D. Chamberlain, T. A. Brodie, Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J. Pharmacol. Exp. Ther. 326, 41-50 (2008). (Pubitemid 351872132)
47. J. G. Conway, B. McDonald, J. Parham, B. Keith, D. W. Rusnak, E. Shaw, M. Jansen, P. Lin, A. Payne, R. M. Crosby, J. H. Johnson, L. Frick, M. H. Lin, S. Depee, S. Tadepalli, B. Votta, I. James, K. Fuller, T. J. Chambers, F. C. Kull, S. D. Chamberlain, J. T. Hutchins, Inhibition of colony-stimulatingfactor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc. Natl. Acad. Sci. U.S.A. 102, 16078-16083 (2005). (Pubitemid 41552870)
48. H. Ohno, Y. Uemura, H. Murooka, H. Takanashi, T. Tokieda, Y. Ohzeki, K. Kubo, I. Serizawa, The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur. J. Immunol. 38, 283-291 (2008).
49. R. T. Paniagua, W. H. Robinson, Imatinib for the treatment of rheumatic diseases. Nat. Clin. Pract. Rheumatol. 3, 190-191 (2007). (Pubitemid 46860398)
50. W. J. Boyle, W. S. Simonet, D. L. Lacey, Osteoclast differentiation and activation. Nature 423, 337-342 (2003). (Pubitemid 40852708)
51. T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M. T. Gillespie, T. J. Martin, Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357 (1999). (Pubitemid 30649812)
52. G. J. Bergman, M. C. Hochberg, M. Boers, N. Wintfeld, A. Kielhorn, J. P. Jansen, Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin. Arthritis Rheum. 39, 425-441 (2010).
53. J. C. Grivel, L. Margolis, Use of human tissue explants to study human infectious agents. Nat. Protoc. 4, 256-269 (2009).
54. Acknowledgments: We thank Y. Iwakura (Institute of Medical Science, University of Tokyo) and T. Reno (Centre National de Recherche Scientifique UMR5201, Lyon, France) for supplying the animals used in this study. We thank T. Al Saati and F. Capilla (Plateau d'Histolopathologie Expérimentale, Institut Fédératif de Recherche Bio-Médicale de Toulouse) for performing histologic assays. Funding: This research was supported by grants from the Fondation Arthritis and Université Paul Sabatier. M.H. was supported by a fellowship from Société Française de Rhumatologie. Author contributions: M.H. planned and performed all in vitro and in vivo experiments, except reverse transcription-PCR (RT-PCR) assays on human monocytes, and analyzed the data. M.P. initiated osteoclast differentiation experiments and analyzed the data. M.B. participated in mice experiments and performed RT-PCR assays on human monocytes. D.N. performed all the statistical analyses. R.A.E., J.-J.F., and A.C. analyzed and discussed the results. C.-O.T., A.-M.C., and J.-P.M. supervised chemical syntheses and provided dendrimer batches. R.P. and J.-L.D. supervised the research. M.H., R.P., and J.-L.D. wrote the paper. Competing interests: Dendrimers ABP, AMP, and PPI are protected in pending patents WO 2006024769 and WO 2010013086. The authors declare that they have no other competing financial interests.